Novartis raises outlook, maps out Sandoz spin-off
By Ludwig Burger FRANKFURT (Reuters) -Novartis on Tuesday raised its full-year earnings guidance on strong drug sales and mapped out
2023-07-18 13:52
Bausch + Lomb to buy dry-eye drug from Novartis for $1.75 billion - WSJ
Bausch + Lomb Corp will pay $1.75 billion to acquire a dry-eye drug from Swiss pharmaceutical giant Novartis,
2023-06-30 19:22
Novartis names Sandoz board members ahead of spin-off
ZURICH Novartis on Monday named the intended new board members of Sandoz, the generics business it plans to
2023-05-15 14:48